Search Results

GemVax & KAEL Co., Ltd. a clinical stage company developing a novel peptide drug based on telomerase modification has released further positive data at the Korean Dementia Association’s Fall Conference from a Phase II trial in Alzheimer’s disease of lead candidate GV1001

GemVax & KAEL Co., Ltd. has announced that a paper on GV1001, a novel Alzheimer’s treatment based on telomerase modification, was published on March 26th in the SCI-grade international journal ‘Alzheimer’s Research & Therapy’.

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro altogether.

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

GemVax & KAEL a clinical stage company developing novel immunotherapies based on telomerase modification announced the decision to apply for an expanded access IND for its lead candidate GV1001 to include additional investigational groups in Alzheimer’s, a disease the WHO estimates to affect 24 million people worldwide, in its clinical development program.

The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite mounting pressure from President Trump for pharma companies to re-shore their manufacturing operations.

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.

Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.